Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced a $20 million Common Stock Purchase Agreement with Aspire Capital on Sept. 14, 2020. The agreement allows Aspire Capital to purchase shares over a span of 30 months, with timing controlled by aTyr. This deal provides aTyr with flexible capital access to support its clinical programs, including ATYR1923 for pulmonary sarcoidosis and COVID-19 complications. Notably, aTyr retains the option to terminate the agreement without penalty. The funding aims to enhance its innovative therapies focused on immunological pathways.
aTyr Pharma (Nasdaq: LIFE) announced its participation in two key investor conferences in September 2020. Sanjay S. Shukla, M.D., President and CEO, will provide updates at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 10:30 a.m. ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:50 a.m. ET. Both events will be held virtually, and presentations will be available for replay on the company's website for 90 days post-event.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported its second quarter results, noting a positive shift in enrollment for the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis despite initial COVID-19 disruptions. A Phase 2 trial for ATYR1923 in COVID-19 patients with severe respiratory issues has commenced with promising initial safety results. Financially, total revenues reached $8.3 million for the first half of 2020, largely due to license agreements, while R&D expenses rose to $8.0 million driven by clinical activities. Cash reserves stood at $41.4 million as of June 30, 2020.
aTyr Pharma has announced that its partner, Kyorin Pharmaceutical, has initiated clinical development for ATYR1923 in Japan after receiving approval from the PMDA. The Phase 1 study will focus on safety, pharmacokinetics, and immunogenicity in healthy volunteers. aTyr received an $8 million upfront payment and could earn up to $167 million in milestone payments, along with tiered royalties on sales in Japan. aTyr is also enrolling a Phase 1b/2a trial for pulmonary sarcoidosis and a Phase 2 trial for COVID-19 patients experiencing severe respiratory issues.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced it will report its second quarter 2020 financial results and provide a corporate update on August 13, 2020, after market close. The company focuses on developing innovative medicines targeting novel immunological pathways, with its lead product ATYR1923 aimed at treating inflammatory lung diseases by binding to the neuropilin-2 receptor. The conference call is scheduled for the same day at 5:00 p.m. EDT.
aTyr Pharma (Nasdaq: LIFE) revealed new research linking Neuropilin receptors to SARS-CoV-2 infection, positioning its lead candidate, ATYR1923, as a potential therapeutic for COVID-19 related lung complications. Studies indicate that SARS-CoV-2 Spike protein binds to Neuropilin receptors, enhancing viral entry. ATYR1923, currently undergoing clinical trials for severe respiratory conditions, selectively modulates Neuropilin-2 to reduce inflammation. The research underscores the drug's potential role in combating SARS-CoV-2 infectivity and suggests broader applications in cancer and inflammatory diseases.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, a biotherapeutics company, announced its presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The company will present an abstract titled Domain-Specific Antibodies to Neuropilin 2 Implicate VEGF-C and not Semaphorin 3F in Breast Cancer Stem Cell Function. The poster will be available on the AACR website on the day of the event.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported Q1 2020 results, highlighting significant developments despite COVID-19 disruptions. The company experienced delays in patient enrollment for its Phase 1b/2a trial of ATYR1923 in pulmonary sarcoidosis due to the pandemic. Notably, aTyr secured an $8 million upfront payment from Kyorin for ATYR1923 and raised $20.7 million through a follow-on offering, totaling around $50 million in cash. Furthermore, the FDA accepted an IND for a Phase 2 study of ATYR1923 in severe COVID-19 patients, aiming to evaluate its safety and efficacy.
aTyr Pharma, Inc. (Nasdaq: LIFE) will report its first quarter 2020 financial results on May 12, 2020, after market close. The company is focused on developing innovative medicines targeting novel immunological pathways and is concentrating on its clinical-stage product candidate, ATYR1923, aimed at treating interstitial lung diseases. A conference call and webcast will follow the earnings report at 5:00 p.m. EDT, providing a platform for detailed discussions on the financial results and corporate updates.
aTyr Pharma announces that two abstracts accepted for the 2020 ATS International Conference will be published in the American Journal of Respiratory and Critical Care Medicine. These abstracts highlight the role of ATYR1923, a clinical candidate, in selectively binding to Neuropilin-2 (NRP2), a target in inflammatory conditions. The findings indicate NRP2's presence in sarcoidosis granulomas, showcasing ATYR1923's potential in treating immune-mediated diseases. The ongoing Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis is also emphasized, alongside collaborations aimed at expanding the preclinical pipeline.